Stratos Wealth Partners LTD. Has $41.28 Million Stock Holdings in AbbVie Inc. $ABBV

Stratos Wealth Partners LTD. increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,266 shares of the company’s stock after purchasing an additional 10,346 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in AbbVie were worth $41,276,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Cornerstone Wealth Group LLC increased its holdings in AbbVie by 2.4% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 67,304 shares of the company’s stock valued at $12,493,000 after purchasing an additional 1,571 shares in the last quarter. Alpine Woods Capital Investors LLC raised its position in AbbVie by 1.8% in the 2nd quarter. Alpine Woods Capital Investors LLC now owns 35,403 shares of the company’s stock valued at $6,572,000 after purchasing an additional 642 shares during the last quarter. Finally, Jag Capital Management LLC boosted its stake in AbbVie by 21.0% in the second quarter. Jag Capital Management LLC now owns 1,256 shares of the company’s stock worth $233,000 after purchasing an additional 218 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ABBV shares. BMO Capital Markets restated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. UBS Group reduced their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Citigroup dropped their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Price Performance

AbbVie stock opened at $222.32 on Wednesday. The firm has a market capitalization of $392.93 billion, a price-to-earnings ratio of 94.20, a PEG ratio of 0.78 and a beta of 0.35. The company’s 50 day simple moving average is $223.67 and its 200 day simple moving average is $220.29. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.